To leverage Immatics' TCR platform with Moderna's mRNA technology across therapeutic modalities including bispecifics, cell therapy and cancer vaccines.
Thermo Fisher to identify local labs that will be using its NGS technology and Pfizer will explore ways to enable affordable patient access for NGS testing.
LambdaGen to produce iPSC lines that enhance anti-tumor activity and Plasticell will use its combinatorial screening technology to develop optimal protocols.
ESSA will conduct a Phase 1 trial evaluating the safety, pharmacokinetics, drug-drug interactions, and Janssen will supply apalutamide and abiraterone acetate.
Project will be funded with federal funds from the National Cancer Institute, National Institutes of Health and Department of Health and Human Services.
Lonza will provide kilogram-scale synthesis, purification and stability testing of Cantrixil, and deliver cGMP batches of drug substance for clinical supply.